Concepedia
Statistics
Publications
5
Citations
142
H-Index
Active since
2019
Affiliations
Eli Lilly (United States)(Current)
Providence College
Butler Hospital
Brown University
World Health Organization
Ena Oru is an author at Eli Lilly (United States) specializing in clinical pharmacology, amyloid clearance, and neurodegenerative disorders.
Publications per year
2019–2025
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Kausik K. Ray, Ena Oru, Robert S. Rosenson et al. · The Lancet · 2025 · 64 citations
Pharmacy, Pharmacology, Pharmacotherapy +11
The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?
Tomoyuki Hayashi, Yumie Takeshita, Yvan Hutin et al. · Archives of Public Health · 2021 · 29 citations · Full text
Public Health, Infectious Diseases, Public Health Practice +17
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
Stephen Salloway, Andrew Pain, Elly Lee et al. · Alzheimer s & Dementia · 2025 · 21 citations · Full text
Medicine, Neurology, Pharmacology +17
TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Stephen Salloway, Elly Lee, Michelle Papka et al. · BJPsych Open · 2023 · 18 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
Access to hepatitis C care for people who inject drugs and people in prisons
Ena Oru, Annette Verster · The Lancet. Gastroenterology & hepatology · 2019 · 10 citations
Pharmacy, Community Health, Health Policy +11
1–5 of 5